Author

Tamir Avioz

National Institutes of Health

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Ariel AfekiD· 2 shared Aakanksha VermaiD· 1 shared Adam G. SowalskyiD· 1 shared Albert Baichorov· 1 shared Alejandro A. SchäfferiD· 1 shared Alessandro GennaiD· 1 shared Andrew E. GreensteiniD· 1 shared Anson T. KuiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Ariel AfekORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EpiBinder: A Multimodal Framework for Cell-Type-Specific Prediction and Interpretation of Transcription Factor Binding

Rubén Solozabal, Albert Baichorov, Irina Miodownik, Tamir Avioz, Le Song, Marcos Matabuena, Martin Takáč, Ariel Afek

EpiBinder predicts cell-type-specific TF binding by integrating DNA sequence and epigenetic data, improving prediction accuracy and providing interpretability.

bioRxiv · Aug 19, 2026 · PreprintGenomics

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications

Arunachalam Sekar, Rishita Chatterjee, Boobash Raj Selvadurai, Lipika R. Pal, Aakanksha Verma, Nishanth Belugali Nataraj, Diana Drago Garcia, Suvendu Giri, Alessandro Genna, Feride Karatekin, Nitin Gupta, Mirie Zerbib, Yaron Vinik, Tamir Avioz, Eviatar Weizman, , Yosef Yarden

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.

bioRxiv · Jan 17, 2025 · PreprintCancer Biology